Analyst Reco. NOV Inc.

Equities

NOV

US62955J1034

Oil Related Services and Equipment

Market Closed - Nyse Other stock markets 21:00:02 06/03/2026 GMT			5-day change	1st Jan Change
18.57 ^USD	-2.01%		-8.34%	+18.81%

02-24	Nov Insider Sold Shares Worth $1,405,422, According to a Recent SEC Filing	MT
02-23	Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk	MT

Analyst Reco.

02-23	Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk	MT
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…
02-04	Barclays Upgrades NOV to Equalweight From Underweight, Raises Price Target to $20 From $15	MT
02-04	Analyst recommendations: Booking, PayPal, Fedex, Gartner, Lockheed Martin….
01-15	RBC Capital Adjusts NOV Price Target to $21 From $19, Maintains Outperform Rating	MT
01-14	Analyst recommendations: Rivian, Applied Materials, Coinbase, Intel, Spotify…
11-20	Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating	MT
29/10/25	RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating	MT
09/10/25	RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating	MT
30/07/25	RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating	MT
28/07/25	NOV's Q2 revenue falls but beats expectations	RE
15/05/25	Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating	MT
30/04/25	RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating	MT
24/03/25	Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH…
24/03/25	RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target	MT
06/02/25	RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating	MT
15/01/25	Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25	MT
06/01/25	Seaport Downgrades NOV to Neutral From Buy	MT
06/01/25	Analyst recommendations: AT&T, Boeing, Nike, T-Mobile, Currys...
19/12/24	Piper Sandler Initiates Coverage on NOV With Neutral Rating, $17 Price Target	MT
11/11/24	Citigroup Downgrades NOV to Neutral From Buy, Adjusts Price Target to $18 From $21	MT
28/10/24	Analyst recommendations: Aon, Ciena, Nutanix, Reddit, Resmed...
25/10/24	The Zephirin Group Adjusts Nov's Price Target to $19 from $22; Keeps at Buy	MT
25/10/24	Zephirin Group Cuts Price Target on NOV to $19 From $22, Keeps Buy Medium Risk	MT
10/10/24	RBC Lowers Price Target on NOV to $21 From $24, Keeps Sector Perform Rating	MT